ALX Oncology
ALXO
92 hedge funds and large institutions have $83.1M invested in ALX Oncology in 2024 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 36 closing their positions.
487% more call options, than puts
Call options by funds: $364K | Put options by funds: $62K
82% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 22
7.04% less ownership
Funds ownership: 93.35% → 86.31% (-7%)
18% less funds holding
Funds holding: 112 → 92 (-20)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 36
72% less capital invested
Capital invested by funds: $293M → $83.1M (-$210M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$15.6M |
| 2 |
Millennium Management
New York
|
+$2.52M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.7M |
| 4 |
Two Sigma Advisers
New York
|
+$1.61M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$21.7M |
| 2 |
O
OrbiMed
New York
|
-$11.4M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$9.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.25M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.83M |
ALXO Hedge Fund Activity: Q3 2024 in Review
92 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2024, worth a combined $83.1M — down 72% from $293M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ALXO and 17 opened new positions — a net loss of 19 holders — while 22 trimmed existing stakes and 40 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $15.6M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $21.7M sold.
- 92 institutional investors held ALX Oncology (ALXO) as of Q3 2024, down from 112 in Q2 2024.
- Funds reported $83.1M of ALX Oncology stock for Q3 2024, down 72% quarter-over-quarter.
- 17 funds opened new ALX Oncology positions in Q3 2024 and 36 closed out, a net change of -19 holders.
- The largest ALX Oncology buyer in Q3 2024 was Tang Capital Management, an estimated $15.6M added.
- The largest ALX Oncology seller in Q3 2024 was Vestal Point Capital, an estimated $21.7M sold.
Based on aggregated 13F filings for Q3 2024.